Sat, Mar 17, 2018
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers June 2013

Focus - The plight of emerging managers, and the general partnership solution


With the increased compliance and regulatory oversight, small and emerging fund managers have to deal with higher costs while at the same time struggle to attract assets; they are being pinched by those two different critical business components. Mrs. Jones of Rothstein Kass describes the current trends and challenges that small and emerging managers are currently encountering, and Mr. Allan of LAIC proposes a solution.

It never was easy to launch a new business, including a new hedge fund. But why has it become so much more challenging of late? According to Meredith Jones , director of research at Rothstein Kass, a large U.S. accounting and auditing firm, this is due to a flight to quality that took place after the 2008 crisis and the Madoff scandal. This flight to quality meant investors going to the larger fund managers.

Meredith Jones Now, around 90% of the industry's capital is in the billion dollar club. The remaining 9,600 funds, she tells Opalesque, are struggling to get assets and keep their business alive. If this goes on, she adds, "it can have the unfortunate effect of homogenizing the industry, because a lot of larger firms tend to look fairly similar, they tend to become more multi-strategy firms at that point in order to put the money to work. And a lot of the alpha is actually in these smaller funds."

Indeed, empirical data clearly shows that young funds (less than four years old) and smaller funds (with less than $100m) outperform their more tenured and larger competitors.



Jones explains why smaller funds produce the alpha:


To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Performance - Hedge fund mojo is back with investor hopes at six-year high, These hedge funds produce the most consistently great results[more]

    Hedge fund mojo is back with investor hopes at six-year high From Hedge funds on the heels of a surprisingly strong performance in 2017 are raising hopes for an encore. Investors expect their managers to return 8.5 percent in 2018, according to a Credit Suisse Group AG sur

  2. Investing - Hedge funds amass big bets against world's leading advertisers, Investor Elliott Management buys tiny stake in Wipro[more]

    Hedge funds amass big bets against world's leading advertisers From Hedge funds have amassed bearish bets of more than $3bn against the world's largest advertising companies in an attempt to profit as the industry undergoes ongoing wrenching disruption and slowing growth. Funds i

  3. News Briefs - Investcorp to launch a $100 million PE fund for Omani pension funds[more]

    Bahrain-based investment firm Investcorp will soon launch a $100 million fund dedicated to Oman's Pension Funds as part of its investment plan. 'The Opportunities Fund' will be focused on private equity investments in the U.S. and Europe and will target mid-sized companies across a broad range of se

  4. DoubleLine's Gundlach sees U.S. 10-year Treasury yield rising, weighing on stocks[more]

    From Reuters/ Jeffrey Gundlach, the chief executive of DoubleLine Capital and known on Wall Street as the "Bond King," said on Tuesday the yield on the U.S. 10-year Treasury note will likely move higher and pressure riskier assets including equities and junk bonds. Gundlach, on an

  5. SEC charges Theranos CEO Holmes with fraud[more]

    Bailey McCann, Opalesque New York: The SEC has charged Elizabeth Holmes, founder and CEO of Theranos and its former President Ramesh "Sunny" Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about t